Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Pacific Biosciences of California, Inc. on June 16, 2021. The meeting was conducted virtually via live audio webcast.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes are reported in this filing. The document details the outcomes of two shareholder proposals:
- Proposal 1: Election of three Class II Directors (Randy Livingston, Marshall Mohr, and Hannah Valantine, M.D.) to serve until the 2024 annual meeting.
- Proposal 2: Ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the election results for the three Class II directors, noting that Marshall Mohr received a significantly higher number of "Against" votes (19,289,521) compared to the other nominees.
- Confirm the ratification of Ernst & Young LLP as the auditor for the 2021 fiscal year.
- Review the definitive proxy statement filed on April 30, 2021, for detailed descriptions of the proposals and director biographies.